Current Prostate Reports

, Volume 6, Issue 4, pp 149–154

Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors



Gonadotropin-releasing hormone (GnRH) agonists are the mainstay of treatment for recurrent and metastatic prostate cancer. GnRH agonists are also an important part of therapy for many men with localized or locally advanced prostate cancer. Although GnRH agonists improve survival in certain settings, they involve adverse effects including vasomotor flushing, obesity, and osteoporosis. This article describes the evidence that GnRH agonists increase risk for diabetes and cardiovascular disease and reviews the potential mechanisms for treatment-related morbidity.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA 2005, 294:238–244.PubMedCrossRefGoogle Scholar
  2. 2.
    Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR: National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003, 95:981–989.PubMedCrossRefGoogle Scholar
  3. 3.
    Barry MJ, Delorenzo MA, Walker-Corkery ES, et al.: The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int 2006, 98:973–978.PubMedCrossRefGoogle Scholar
  4. 4.
    Shahinian VB, Kuo YF, Freeman JL, et al.: Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005, 103:1615–1624.PubMedCrossRefGoogle Scholar
  5. 5.
    Keating NL, O’Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation for prostate cancer. J Clin Oncol 2006, 24:4448–4456.PubMedCrossRefGoogle Scholar
  6. 6.
    Saigal CS, Gore JL, Krupski TL, et al.: Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007, 110:1493–1500.PubMedCrossRefGoogle Scholar
  7. 7.
    Tsai HK, D’Amico AV, Sadetsky N, et al.: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007, 99:1516–1524.PubMedCrossRefGoogle Scholar
  8. 8.
    D’Amico AV, Denham JW, Crook J, et al.: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007, 25:2420–2425.PubMedCrossRefGoogle Scholar
  9. 9.
    Efstathiou JA, Bae K, Shipley WU, et al.: Cardiovascular mortality and duration of androgen deprivation therapy for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008 (in press).Google Scholar
  10. 10.
    The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984, 311:1281–1286.CrossRefGoogle Scholar
  11. 11.
    Garnick MB: Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial. Urology 1986, 27:21–28.PubMedCrossRefGoogle Scholar
  12. 12.
    Vermeulen A, Goemaere S, Kaufman JM: Testosterone, body composition and aging. J Endocrinol Invest 1999, 22:110–116.PubMedGoogle Scholar
  13. 13.
    Tayek JA, Heber D, Byerley LO, et al.: Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism 1990, 39:1314–1319.PubMedCrossRefGoogle Scholar
  14. 14.
    Smith JC, Bennett S, Evans LM, et al.: The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001, 86:4261–4267.PubMedCrossRefGoogle Scholar
  15. 15.
    Smith MR, Finkelstein JS, McGovern FJ, et al.: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87:599–603.PubMedCrossRefGoogle Scholar
  16. 16.
    Berruti A, Dogliotti L, Terrone C, et al.: Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002, 167:2361–2367; discussion 2367.PubMedCrossRefGoogle Scholar
  17. 17.
    Smith M: Changes in fat and lean body mass during androgen deprivation therapy for prostate cancer. Urology 2004, 63:742–745.PubMedCrossRefGoogle Scholar
  18. 18.
    Lee H, McGovern K, Finkelstein JS, Smith MR: Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005, 104:1633–1637.PubMedCrossRefGoogle Scholar
  19. 19.
    Page ST, Herbst KL, Amory JK, et al.: Testosterone administration suppresses adiponectin levels in men. J Androl 2005, 26:85–92.PubMedGoogle Scholar
  20. 20.
    Smith MR, Lee H, Fallon MA, Nathan DM: Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008 (in press).Google Scholar
  21. 21.
    Smith MR, Lee H, McGovern FJ, et al.: Metabolic changes during gonadotropin releasing hormone (GnRH) agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008 (in press).Google Scholar
  22. 22.
    Hotta K, Funahashi T, Arita Y, et al.: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595–1599.PubMedCrossRefGoogle Scholar
  23. 23.
    Kumada M, Kihara S, Sumitsuji S, et al.: Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23:85–89.PubMedCrossRefGoogle Scholar
  24. 24.
    Rothenbacher D, Brenner H, Marz W, Koenig W: Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005, 26:1640–1646.PubMedCrossRefGoogle Scholar
  25. 25.
    Pischon T, Girman CJ, Hotamisligil GS, et al.: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730–1737.PubMedCrossRefGoogle Scholar
  26. 26.
    Lindsay RS, Resnick HE, Zhu J, et al.: Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005, 25:e15–e16.PubMedCrossRefGoogle Scholar
  27. 27.
    Lawlor DA, Davey Smith G, Ebrahim S, et al.: Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005, 90:5677–5683.PubMedCrossRefGoogle Scholar
  28. 28.
    Laughlin GA, Barrett-Connor E, May S, Langenberg C: Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007, 165:164–174.PubMedCrossRefGoogle Scholar
  29. 29.
    Eri LM, Urdal P, Bechensteen AG: Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995, 154:100–104.PubMedCrossRefGoogle Scholar
  30. 30.
    Smith MR, Lee H, Nathan DM: Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91:1305–1308.PubMedCrossRefGoogle Scholar
  31. 31.
    American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2008, 31(Suppl 1):S55–S60.CrossRefGoogle Scholar
  32. 32.
    Despres JP, Lamarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952–957.PubMedCrossRefGoogle Scholar
  33. 33.
    Pyorala M, Miettinen H, Laakso M, Pyorala K: Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998, 98:398–404.PubMedCrossRefGoogle Scholar
  34. 34.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143–3421.Google Scholar
  35. 35.
    Braga-Basaria M, Dobs AS, Muller DC, et al.: Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006, 24:3979–3983.PubMedCrossRefGoogle Scholar
  36. 36.
    Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289–2304.PubMedCrossRefGoogle Scholar
  37. 37.
    Ferrannini E: Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 2007, 92:396–398.PubMedCrossRefGoogle Scholar
  38. 38.
    Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.PubMedCrossRefGoogle Scholar
  39. 39.
    Smith MR: Selective estrogen receptor modulators to prevent treatment-related osteoporosis. Rev Urol 2005, 7(Suppl 3):S30–S35.PubMedGoogle Scholar
  40. 40.
    Erkkola R, Mattila L, Powles T, et al.: Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre-and post-menopausal women. Breast Cancer Res Treat 2005, 93:277–287.PubMedCrossRefGoogle Scholar
  41. 41.
    Joensuu H, Holli K, Oksanen H, Valavaara R: Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 2000, 63:225–234.PubMedCrossRefGoogle Scholar
  42. 42.
    Saarto T, Blomqvist C, Ehnholm C, et al.: Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996, 14:429–433.PubMedGoogle Scholar
  43. 43.
    Kusama M, Miyauchi K, Aoyama H, et al.: Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Breast Cancer Res Treat 2004, 88:1–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Smith M, Malkowicz SB, Chu F, et al.: Toremifene improves lipid profiles in men receiving androgen deprivation therapy for prostate cancer-interim analysis of a multicenter phase III study. J Clin Oncol 2008 (in press).Google Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Yawkey Center 7038Massachusetts General Hospital Cancer CenterBostonUSA

Personalised recommendations